

## Bayer-sponsored Symposium

### *What if? Protecting your patients with AF from stroke, no matter their journey*

**Sunday, 03 April, 10:55 - 11:40 CEST**

**Chair:** John Camm

**Speakers:** Keith Fox, Emma Svenberg, Tatjana Potpara

#### Summary




This symposium focused on the management of Julia, a fictional patient with diabetes and AF, and explored how our stroke prevention strategies are affected when common challenges arise.

**Professor Emma Svenberg** discussed the importance of screening patients like Julia for AF and showed how the early detection of AF is the first step in protecting your patients from potentially devastating outcomes.

**Professor Tatjana Potpara** outlined the breadth and depth of evidence for NOAC treatment in challenging patient populations of patients with AF and co-morbid CKD and diabetes and demonstrated that NOACs like rivaroxaban can help slow the decline of kidney function.

**Professor Keith Fox** revealed how results from trials such as PIONEER AF-PCI have resulted in guidelines moving away from recommendations for prolonged triple therapy and towards the use of dual therapy in patients with AF undergoing elective PCI.

Finally, **Professor John Camm** demonstrated that NOACs have been proven to provide consistent protection as your patients get older and explored how you can support them to adhere to their treatment regimen.



**Find out more**

[go.bayer.com/ehra2022](https://go.bayer.com/ehra2022)

